sch-23390

**SCH-23390** is a synthetic *halobenzazepine* compound and is considered the prototypical *dopamine D1-like receptor antagonist*. It binds with **high affinity** and **selectivity** to dopamine D1 and D5 receptor subtypes (Ki approximately 0.2–0.3 nM), and exhibits moderate/high affinity for the 5-HT2 and 5-HT1C (now known as 5-HT2C) serotonin receptor subtypes at higher concentrations. Although originally investigated as a potential therapy for Parkinson’s disease, schizophrenia, and depression, clinical development was discontinued due to limited efficacy and adverse effects, including akathisia. SCH-23390 (often used as its hydrochloride salt) is now primarily employed as a **pharmacological tool** in neuroscience research, including studies of the dopaminergic system, PET imaging, and receptor binding assays[1][2][3][4][5][7][8][10].

Other names

halobenzazepineR-(+)-SCH-23390(R)-8-chloro-3-methyl-5-phenyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-ol(R)-2,3,4,5-tetrahydro-8-chloro-3-methyl-5-phenyl-1H-3-benzazepin-7-olSCH-23390 hydrochlorideSCH23390 hydrochlorideSCH 23390 hydrochlorideR-(+)-SCH-23390 hydrochlorideSCH-23390 (hydrochloride)